Search
idecabtagene vicleucel (Abecma)
Indications:
- treatment of multiple myeloma after 4 or more prior lines of therapy
Dosage:
- 300-460 million CAR-positive T cells
* 100 mL 4,600,000 cells/mL injection
* 70 mL 6,571,428 cells/mL injection
* 30 mL 15,333,333 cells/mL injection
Adverse effects:
- most common
- cytokine release syndrome
- infections
- fatigue
- musculoskeletal pain
- hypogammaglobulinemia.
* boxed warning
- cytokine release syndrome
- neurologic toxicities
- hemophagocytic lymphohistiocytosis/macrophage activation syndrome
- prolonged cytopenias
Mechanism of action:
- cell-based gene therapy
- B-cell maturation antigen-directed genetically modified autologous CAR T-cell therapy
General
chimeric antigen-receptor (CAR) T-cell therapy; tisagenlecleucel; CTL019 (Kymriah)
antineoplastic agent (chemotherapeutic agent)
References
- FDA Drug Approvals. March 26, 2021
FDA approves idecabtagene vicleucel for multiple myeloma
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-idecabtagene-vicleucel-multiple-myeloma
- Nelson R
'Phenomenal' Results with CAR T-Cells in R/R Multiple Myeloma.
Medscape. March 2, 2021
https://www.medscape.com/viewarticle/946733
- ABECMA HIGHLIGHTS OF PRESCRIBING INFORMATION
https://www.fda.gov/media/147055/download